- Home
- JZXN vs SPRO Comparison
JZXN vs SPRO Comparison
Compare JZXN & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- SPRO
- Stock Information
- Founded
- JZXN 2019
- SPRO 2013
- Country
- JZXN China
- SPRO United States
- Employees
- JZXN N/A
- SPRO N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- SPRO Health Care
- Exchange
- JZXN Nasdaq
- SPRO Nasdaq
- Market Cap
- JZXN 45.5M
- SPRO 45.7M
- IPO Year
- JZXN 2021
- SPRO 2017
- Fundamental
- Price
- JZXN $3.84
- SPRO $0.70
- Analyst Decision
- JZXN
- SPRO Buy
- Analyst Count
- JZXN 0
- SPRO 4
- Target Price
- JZXN N/A
- SPRO $5.00
- AVG Volume (30 Days)
- JZXN 33.0K
- SPRO 118.7K
- Earning Date
- JZXN 05-19-2025
- SPRO 03-27-2025
- Dividend Yield
- JZXN N/A
- SPRO N/A
- EPS Growth
- JZXN N/A
- SPRO N/A
- EPS
- JZXN N/A
- SPRO N/A
- Revenue
- JZXN $1,400,139.00
- SPRO $47,977,000.00
- Revenue This Year
- JZXN N/A
- SPRO N/A
- Revenue Next Year
- JZXN N/A
- SPRO N/A
- P/E Ratio
- JZXN N/A
- SPRO N/A
- Revenue Growth
- JZXN N/A
- SPRO N/A
- 52 Week Low
- JZXN $1.00
- SPRO $0.70
- 52 Week High
- JZXN $67.60
- SPRO $1.81
- Technical
- Relative Strength Index (RSI)
- JZXN 47.54
- SPRO 36.17
- Support Level
- JZXN $3.00
- SPRO $0.75
- Resistance Level
- JZXN $5.30
- SPRO $0.80
- Average True Range (ATR)
- JZXN 0.75
- SPRO 0.05
- MACD
- JZXN -0.12
- SPRO -0.00
- Stochastic Oscillator
- JZXN 50.00
- SPRO 8.33
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.